The growth in Artificial Intelligence (AI) has proliferated into various sectors. A lot of startups across the world are creating new approaches and seeking after the inventive business models in a bid to alter the pharmaceutical businesses.
LabGenius has announced today that it has raised over $10 million (€11.5 million) in its Series A financing round. LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.
The Series A investment round was led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Gigafund, Air Street Capital and existing investors. The round also included participation from Recursion Pharmaceuticals’ Founder & CEO Chris Gibson as well as Inovia Capital General Partner Patrick Pichette who was formerly Google’s CFO. Zavain Dar, Partner at Lux Capital and Nan Li, Managing Director at Obvious Ventures, will join the company’s board of directors.
Nan Li, Managing Director at Obvious Ventures, said:
Silicon Canals for more European technology news.
https://siliconcanals.com/news/sponsh-dutch-startup-extract-water-air-fight-water-shortage%e2%80%8c/
01
Dutch at Slush 2024: Meet the four 4TU startups who are fundraising at the world’s most founder-focused event